Join to View Full Profile
2000 Circle of Hope DrSalt Lake City, UT 84112
Dr. Swami is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 2016 - 2019
St Barnabas HospitalResidency, Internal Medicine, 2011 - 2014
Sawai Man Singh Medical CollegeClass of 2007- University of Iowa Hospitals and ClinicsResidency, Internal Medicine
Certifications & Licensure
UT State Medical License 2018 - 2026
MT State Medical License 2021 - 2025
NV State Medical License 2021 - 2025
ID State Medical License 2021 - 2024
WY State Medical License 2021 - 2024
CO State Medical License 2021 - 2023
IA State Medical License 2014 - 2020
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial Start of enrollment: 2022 Mar 11
Roles: Contact, Principal Investigator
- Bortezomib in Patients with Metastatic Castration-Resistant Prostate Cancer with PTEN Deletion Start of enrollment: 2024 Mar 11
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- T-cell Engagers in Prostate Cancer.Chadi Hage Chehade, Zeynep Irem Ozay, Micah Ostrowski, Chiara Mercinelli, Georges Gebrael
European Urology. 2025-05-01 - Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial.Rohit K Jain, Umang Swami, Mehmet A Bilen, Georges Gebrael, Kenneth M Boucher
European Urology Oncology. 2025-04-29 - Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer.Hyejung Lee, Jincheng Shen, Muhammad Zaki Fadlullah, Anna Neibling, Claire Hanson
Clinical Proteomics. 2025-04-18
Authored Content
- Real-World Trends in Bone Health Agent Use for Metastatic Prostate Cancer - Umang SwamiFebruary 2025
Press Mentions
- Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate CancerDecember 28th, 2020
Successful Discontinuation of PD-1 Inhibitors in Metastatic MelanomaAugust 20th, 2020
What Contributed to the Decrease in Melanoma Incidence in Younger Individuals?March 6th, 2020- Join now to see all
Other Languages
- Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
